Barclays initiated coverage on Qiagen with a new price target
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2025 | $55.00 | Overweight | Barclays |
| 4/4/2025 | Buy → Neutral | Redburn Atlantic | |
| 2/19/2025 | $52.00 → $42.00 | Outperform → Neutral | Robert W. Baird |
| 1/6/2025 | $48.00 | Overweight → Equal-Weight | Morgan Stanley |
| 12/10/2024 | $42.50 → $54.00 | Hold → Buy | Jefferies |
| 10/17/2024 | $49.00 | Buy → Hold | HSBC Securities |
| 6/27/2024 | $50.00 | Peer Perform → Outperform | Wolfe Research |
| 12/19/2023 | $44.00 | Equal Weight | Wells Fargo |
Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00
Redburn Atlantic downgraded Qiagen from Buy to Neutral
Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously
SD - QIAGEN N.V. (0001015820) (Filer)
SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)
6-K - QIAGEN N.V. (0001015820) (Filer)